In a robust decision handed down by the English Court of Appeal, Novartis has been awarded an interim injunction against Hospira to prevent sales of generic zoledronic acid in the UK despite Novartis’ patents having been declared invalid by the English High Court. The Court of Appeal judgment represents a significant victory for Novartis and other innovators. This article discusses how this decision impacts innovators and generic companies alike, as well as the practical steps that parties should consider prior to the launch of a generic product.
Members-only access
To access the full resource, you must be a
member.
Already a member?
Login to unlock.
Login
Not an ACC member?
Gain access to a comprehensive collection of global
resources for in-house counsel
Sign
up for a 30-day trial
Region:
United Kingdom
The information in any resource collected in this virtual library should
not be construed as legal advice or legal opinion on specific facts and should not be considered representative of the views of its authors, its sponsors, and/or ACC. These resources are not intended as a definitive statement on the subject addressed. Rather, they are intended to serve as a tool providing practical advice and references for the busy in-house practitioner and other readers.